Magnitude Biosciences Raises £1.3m to Scale Drug Discovery Platform

Magnitude Biosciences secures £1.3 million to scale drug discovery platform

NETPark-based Magnitude Biosciences has secured £1.3 million to accelerate the commercialisation of VivoScan™, its whole-organism drug screening platform.The investment will help the Durham University spinout expand its work with pharmaceutical companies, increase automation and recruit new members of staff.Supporting faster drug discoveryMagnitude Biosciences is a specialist contract research organisation that helps pharmaceutical and biotechno…

Magnitude Biosciences secures £1.3m to scale breakthrough drug discovery platform

Magnitude Biosciences secures £1.3m to scale breakthrough drug discovery platform

Magnitude Biosciences raises £1.3m to scale drug discovery platform

Durham University spinout Magnitude Biosciences has raised £1.3m to scale its drug discovery platform and expand its work with pharmaceutical companies. The life sciences company has developed VivoScan™, a high-throughput screening platform that uses C. elegans nematode worms to test potential drug candidates in a whole organism. Magnitude combines the worms with imaging, machine learning, […]

Magnitude Biosciences secures €1.5 million investment to scale in-vivo drug discovery platform

Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, has secured €1.5 million (£1.3 million) in funding to accelerate the commercialisation of VivoScanTM, its proprietary in vivo high-throughput screening (HTS) platform. Northstar Ventures led the round through the North East Spinout Inspire Fund, the North East Innovation Fund and the Northstar EIS […]

Biosciences firm 'set to evolve' with £1.3 million boost

A healthcare firm says it is primed to “enter the next stage of its evolution” after securing £1.3 million funding Magnitude Biosciences has been backed to expand its VivoScan screening platform. Bosses say the seven-figure support will bolster the development of its technology, which supports pharma and biotech operators to identify new…